Varenzin is now available to practices across the UK and offers pet owners “a first-of-its-kind oral suspension that can be administered daily at home”. In clinical studies, 68% of cats achieved treatment success after one month.
Presented as a once-daily fish oil-flavoured formulation, with “a strong acceptance rate of 88%”, the product is designed to stimulate a cat’s natural endogenous erythropoietin production (EPO), which is often reduced in cats with kidney disease.
The active substance, molidustat, belongs to a novel class of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors and works by activating the body’s natural response to low oxygen levels, boosting EPO production and thereby stimulating red blood cell production by the bone marrow, Elanco states.
https://my.elanco.com/us/campaign/varenzin